US › Healthcare

Anavex Life Sciences Corp (AVXL)

US · Healthcare · Biotechnology

$3.15+6.78%
Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue
$0
Net profit
$-5.7M
Profit YoY
+53.1%
EPS
$-0.13
EPS estimate
$-0.07

EPS came in at -0.13 against a street estimate of -0.07 — a miss of 85.7%.

Key statistics

Market cap
$273.4M
Forward P/E
3.9
P/B
2.10
Book value
$1.09
EPS (TTM)
$-0.39
52-week high
$11.70
52-week low
$2.25
50-day MA
$2.61
200-day MA
$4.05
Beta
1.14

Analyst view

Analysts rate Anavex Life Sciences Corp a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $20.00.

Shareholding

Insiders
3.12%
Institutions
43.82%

Largest institutional holders

FundStake
BlackRock Inc8.21%
Vanguard Group Inc5.43%
State Street Corp4.87%
Vanguard Capital Management, LLC4.17%
Two Sigma Investments LLC3.50%
Geode Capital Management, LLC2.36%
Two Sigma Advisers, LLC1.31%
Susquehanna International Group, LLP1.07%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Anavex Life Sciences Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.